Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Gavin P. Robertson, Ph.D. is Professor of Pharmacology, Pathology, Dermatology and Surgery at Penn State University, Director, Penn State Melanoma Center, and Director, Foreman Foundation Melanoma Research Laboratory in the Department of Pharmacology and Penn State Cancer Institute. His research focuses on malignant melanoma; the most deadly form of skin cancer, with the goal of unraveling the biology and signaling pathways involved in melanoma tumor development, and in developing the next generation of therapeutic agents to treat this disease. The discovery of Akt3 involvement in ~70% of human melanomas led to the development of ISC-4, which targets Akt3 signaling. Nanotechnology and bioengineering are enabling the use of nanoliposomes and ultrasound that deliver therapeutic products into melanoma cells, leading to the development of Nanolipolee-007. His translational research program is focused on developing better therapeutics based on the biology of the disease. He holds a Ph.D., University of California, Riverside, and completed his Postdoctoral Training at the Ludwig Institute for Cancer Research in San Diego.
Drug Resistance,Bone Marrow Cancer,Cancer Therapies, Nanotechnology, Nanobiotechnology, Nanocomposites, Nanobiopharmaceutics, Nanoelectronics, Nanomedicine, Nanotoxicology
Raghavendra Gowda, Nathan R Jones, Shubhadeep Banerjee and Gavin P Robertson
Review Article: J Nanomed Nanotechnol 2013, 4:184